Allergen Avoidance in Pediatric Asthma: Dust Mites, Cockroaches, and Mice
Allergy testing is recommended for children with persistent asthma so that avoidance counseling can be aimed at the triggers that actually matter for that child. But the evidence on which avoidance measures change asthma outcomes is far from uniform.
For house dust mites, physical and chemical control measures — including impermeable mattress covers — reliably lower measured allergen levels yet have not been shown to prevent allergic disease or improve established asthma in controlled trials. For cockroaches, the picture is different: high allergen exposure drives hospitalizations independent of sensitization status, and a single professional bait application has been shown to cut both cockroach counts and asthma morbidity in New Orleans children. Local ecology matters too — American cockroaches here largely originate outdoors, so control sometimes has to reach the yard. For mouse allergen, education alone (traps and sealing entry points) can match professional integrated pest management.
This page distills those trials into practical, Gulf-South–relevant guidance for pediatric teams.
Pediatrics from the Parishes
A Conference Reimagined
August 13 - 16, 2026
The Roosevelt Hotel • New Orleans, LA
Allergy testing for persistent asthma
Identifying a child's specific sensitizations focuses avoidance counseling. In the Gulf-South (Region 6), a regional respiratory panel typically screens for perennial indoor allergens, molds, and locally relevant pollens. Panel contents vary slightly by reference laboratory:
| Category | Typical allergens screened |
|---|---|
| Animal / perennial | Cat dander, dog dander, mouse (urine or epithelium), cockroach |
| Dust mites | Dermatophagoides farinae, D. pteronyssinus |
| Molds | Alternaria, Aspergillus, Cladosporium/Hormodendrum, Penicillium (± Mucor) |
| Tree pollens | Elm, maple, mountain cedar, mulberry, oak, pecan/hickory, birch, walnut/cottonwood, ash |
| Grass pollens | Timothy, Bermuda |
| Weed pollens | Rough marshelder, pigweed/Russian thistle, short ragweed (± nettle) |
Exact panel composition differs among Quest, Labcorp, and ARUP; confirm the components offered by your reference lab.
Pollen and mold seasons
- Trees: early to late spring.
- Grasses: late spring to early fall.
- Weeds: early fall until the cold of winter.
- Mold spores: spring through fall, fluctuating with humidity; indoor spikes track water leaks and resolve when leaks are fixed.
- Pollen levels generally peak from morning into early afternoon.
- Thunderstorms can shatter pollen grains and release certain mold spores, occasionally triggering flares.
- FDA-approved sublingual tablets exist for grass-pollen and ragweed-pollen allergy.
House dust mites
Dust mites are a common sensitizer, but the trial evidence for physical and chemical avoidance measures has been consistently disappointing for asthma outcomes.
Control measures for established asthma (Cochrane 2008)
A Cochrane systematic review pooled 54 trials (about 3,002 patients) of physical methods (most commonly mattress encasings), chemical methods, and combinations. Across the pre-specified outcomes, differences between intervention and control were essentially null:
| Outcome | Effect estimate (95% CI) |
|---|---|
| Morning peak flow | Mean difference 0.00 (−0.10 to 0.10) |
| Patients reporting improvement | Relative risk 1.01 (0.80 to 1.27) |
| Asthma symptom score | Standardized mean difference −0.04 (−0.15 to 0.07) |
| Medication use | Standardized mean difference −0.06 (−0.18 to 0.07) |
The authors concluded that chemical and physical measures aimed at reducing house dust mite allergen exposure could not be recommended on this evidence.
Prevention of allergic disease (Arroyave 2014 meta-analysis)
A later meta-analysis examined impermeable mattress covers for both primary prevention (7 trials, n ≈ 3,461) and tertiary prevention (17 trials, n ≈ 1,671). No clinically meaningful benefit was found:
Primary prevention — pooled RR
- Dust-mite sensitization: 0.97 (0.62–1.51)
- Wheeze: 0.92 (0.81–1.05)
- Asthma: 0.85 (0.70–1.02)
- Allergic rhinitis: 1.03 (0.90–1.19)
- Atopic dermatitis: 1.05 (0.84–1.32)
Tertiary prevention — pooled SMD
- Peak flow: −0.03 (−0.15 to 0.09)
- Asthma symptom score: −0.06 (−0.32 to 0.20)
- Nasal symptom score: −0.39 (−0.88 to 0.11)
- Mattress mite level did fall significantly: −0.79 (−0.98 to −0.60)
So what can help when dust mites truly drive disease?
- Wearing an N-95 respirator while cleaning, or leaving the area for ~30 minutes afterward.
- Subcutaneous immunotherapy.
- Sublingual immunotherapy (Odactra) — labeled for ages 18 and up at the time of this talk; verify current age indications.
Cockroaches
Cockroach allergen is a major driver of asthma morbidity in urban children, and the relevant species differ by setting. German cockroaches predominate in many inner-city apartments; in warm, humid regions such as New Orleans, American cockroaches (largely outdoor in origin) become prominent.
Cockroach allergen and morbidity (Rosenstreich, NEJM 1997)
In the landmark inner-city asthma study, children who were both sensitized to cockroach and exposed to high cockroach allergen had significantly more asthma-related hospitalizations than other groups (P = 0.001) — an effect not seen for dust mite or cat allergen in the same cohort.
Exposure independent of sensitization (Rabito, 2011)
In 86 atopic asthmatic children in New Orleans, high cockroach-allergen exposure (Bla g 1 > 2 U/g) was associated with markedly higher odds of hospitalization, independent of whether the child tested sensitized. Dust-mite exposure was not associated with morbidity measures.
| Exposure | ≥1 ED visit | ≥1 hospital admission | ≥16 days wheezing |
|---|---|---|---|
| Cockroach (Bla g 1) > 2 U/g | 1.80 (0.70–4.70) | 4.53 (1.43–13.80) | 3.61 (0.65–19.99) |
| Mite (Der p 1) > 2 µg/g | 0.70 (0.25–2.01) | 1.13 (0.35–3.67) | 1.60 (0.37–6.94) |
| Mite (Der f 1) > 2 µg/g | 0.79 (0.29–2.14) | 2.32 (0.79–6.78) | 1.31 (0.31–5.60) |
Does bait alone change outcomes? (Rabito & Carlson, JACI 2017)
A 12-month randomized trial applied insecticidal cockroach bait in the homes of 102 children (ages 5–17) with moderate-to-severe asthma in greater New Orleans. A single professional bait application sharply reduced cockroach counts and improved asthma morbidity versus control:
| Variable | Estimate | 95% CI | P |
|---|---|---|---|
| Cockroaches trapped (β) | 13.14 | 6.88 to 19.39 | <.01 |
| Mean maximum symptom days (β) | 1.82 | 0.14 to 3.50 | .03 |
| ED / unscheduled clinic visits (β) | 1.17 | 0.11 to 2.24 | .03 |
| FEV₁ < 80% predicted (OR) | 5.74 | 1.60 to 20.57 | .01 |
| Households trapped ≥1 roach (OR) | 25.23 | 6.27 to 101.50 | <.01 |
Bait application also raised the proportion of homes brought to low/undetectable Bla g 1, supporting cockroach control as a meaningful asthma intervention.
Where do New Orleans cockroaches come from? (Carlson, Clin Pediatr 2017)
Trapping at 40 New Orleans homes characterized indoor and outdoor niches. A mark-release-recapture study (roaches marked with fluorescent powder — pink for sewer, blue for yard) found that cockroaches released into yards were recovered inside homes, while sewer-released roaches were not — implicating yards, not sewers, as the more important source niche. A yard-applied granule field trial significantly reduced indoor cockroach antigen.
| Location | American — adults / nymphs | German — adults / nymphs | Smokey brown — adults / nymphs |
|---|---|---|---|
| Indoors | 5.53 / 35.32 | 6.38 / 35.32 | 2.13 / 2.13 |
| Storm drain | 21.74 / 4.35 | 0.00 / 0.00 | 33.33 / 1.45 |
| Sewer line | 0.00 / 16.67 | 0.00 / 0.00 | 0.00 / 8.33 |
| Under house | 4.29 / 15.00 | 1.42 / 4.29 | 5.00 / 17.86 |
| Yard | 15.71 / 27.14 | 1.88 / 6.43 | 16.25 / 5.63 |
Mouse allergen
A randomized trial (JAMA 2017) enrolled 361 mouse-sensitized children and adolescents with asthma, comparing professional integrated pest management (IPM) plus education against education alone. Mouse-allergen levels fell dramatically in both arms, and asthma improved equally in both — meaning the education-only package (written materials plus demonstrations of trap use and sealing holes) achieved comparable benefit without professional IPM.
Conclusions
- House dust mites: available avoidance measures lower exposure but do not prevent primary or tertiary allergic disease; consider N-95 use and immunotherapy when mites genuinely drive disease.
- German cockroaches: can be eradicated with insecticidal baits, and this improves asthma outcomes.
- American cockroaches (New Orleans): generally come from outdoors; their role in U.S. clinical disease is probable but not yet substantiated.
- Mouse allergen: can be reduced with education alone (traps, sealing holes), which can improve asthma outcomes.
Selected references
- Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev. 2008.
- Arroyave WD, Rabito FA, Carlson JC, Friedman FE, Stinebaugh SJ. Impermeable dust mite covers in the primary and tertiary prevention of allergic disease: a meta-analysis. Ann Allergy Asthma Immunol. 2014;112(3):237-48.
- Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. 1997;336(19):1356-63.
- Rabito FA, Carlson J, Holt EW, Iqbal S, James MA. Cockroach exposure independent of sensitization status and association with hospitalizations for asthma in inner-city children. Ann Allergy Asthma Immunol. 2011;106(2):103-9.
- Rabito FA, Carlson JC, He H, Werthmann D, Schal C. A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children. J Allergy Clin Immunol. 2017;140(2):565-570.
- Carlson JC, Rabito FA, Werthmann D, Fox M. The distribution and movement of American cockroaches in urban niches of New Orleans. Clin Pediatr. 2017.
- Matsui EC, Perzanowski M, Peng RD, et al. Effect of an integrated pest management intervention on asthma symptoms among mouse-sensitized children and adolescents with asthma: a randomized clinical trial. JAMA. 2017;317(10):1027-1036.
Adapted from “Effective Mitigation of Allergen-Induced Asthma,” a Louisiana Chapter of the American Academy of Pediatrics conference presentation by John C. Carlson, MD, PhD (Tulane University School of Medicine), 2018. Data tables are reconstructed from the cited peer-reviewed sources; original journal figures and photographs are not reproduced. This material is educational and does not indicate an exclusive course of treatment or serve as a standard of medical care; variations accounting for individual circumstances may be appropriate. Verify drug age indications and guidance against current AAP/AAAAI recommendations before applying.